



# Financial Tear Sheet

## Corporate Profile

T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, eliminating the time-consuming sample prep required in current methods. For more information, please visit [www.t2biosystems.com](http://www.t2biosystems.com).

## Primary IR Contact

Investor

Contact Information

**E-mail:**

[ir@T2Biosystems.com](mailto:ir@T2Biosystems.com)

## Stock Performance

### TTOO (Common Stock)

<b>Exchange</b>	NASDAQ (US Dollar)
<b>Price</b>	<b>\$3.90</b>
<b>Change (%)</b>	▼ 0.2 (4.88%)
<b>Volume</b>	136,063
<b>52 Week Low</b>	\$2.50
<b>Market Cap</b>	\$126,133,708
<b>Rolling EPS</b>	-1.97
<b>PE Ratio</b>	0
<b>Shares Outstanding</b>	30,764,319

Data as of 08/17/17 4:00 p.m. ET



Data provided by Nasdaq. Minimum 15 minutes delayed.

## Recent Headlines & Events

08/03/17 - 4:06 p.m.  
T2 Biosystems Reports Second Quarter 2017 Financial Results; Provides Company Update

There are currently no events scheduled.

08/02/17 - 8:00 a.m.  
T2 Biosystems to Present at the 37th Annual Canaccord Genuity Growth Conference

07/27/17 - 8:59 a.m.  
T2 Biosystems Joins Antimicrobials Working Group as First Diagnostic Member

## SEC Filings

Filing Date	Form
08/08/17	8-K
08/04/17	10-Q
06/08/17	4
06/08/17	4

## Corporate Governance

John McDonough	Chief Executive Officer
Joanne Spadaro, Ph.D.	Chief Operations Officer
Tom Lowery, Ph.D.	Chief Scientific Officer
David P. Harding	Chief Commercial Officer
Michael A. Pfaller, MD	Chief Medical Officer
Rahul Dhanda	Senior Vice President, Corporate Development
Michael Gibbs, Esq.	Vice President and General Counsel
Alec Barclay	VP, Product Development & Program Management